SCHEMBL7112167

SCHEMBL7112167

FC(F)(F)c1ccc(-c2csc(Nc3ccc(Cl)c(Cl)c3)n2)cc1

nearest known ligand 0.75

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALOX5 P09917 9/20 0.75
VCP P55072 4/20 0.65
MAPT P10636 5/20 0.55
KDM4E B2RXH2 3/20 0.55
MAPK1 P28482 2/20 0.55
CFTR P13569 1/20 0.54
NPSR1 Q6W5P4 2/20 0.53
MEN1 O00255 2/20 0.53
KMT2A Q03164 2/20 0.53
ESR1 P03372 1/20 0.53
NPY5R Q15761 1/20 0.53
BLM P54132 1/20 0.53
KDM1A O60341 1/20 0.52
AMY1A P0DUB6 2/20 0.51
ALOX15 P16050 2/20 0.51
TSHR P16473 2/20 0.51
TDP1 Q9NUW8 2/20 0.51
DEGS1 O15121 1/20 0.51
MAP4K4 O95819 1/20 0.51
CYP3A4 P08684 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL205448 0.86 ALOX5 (0.65) ALOX5VCPMAPTKDM4EMAPK1
SCHEMBL2648894 0.86 ALOX5 (1.00) ALOX5VCPMAPTKDM4EMAPK1
SCHEMBL208192 0.85 ALOX5 (0.72) ALOX5VCPMAPTMAPK1MEN1
SCHEMBL1885333 0.85 ESR1 (0.72) ALOX5VCPMAPTMAPK1CFTR
SCHEMBL205976 0.85 ALOX5 (0.80) ALOX5VCPMAPTKDM4EMAPK1
SCHEMBL7246864 0.85 ALOX5 (0.79) ALOX5VCPMAPTKDM4EMAPK1
SCHEMBL23539585 0.84 VCP (0.79) ALOX5VCPMAPTKDM4EMAPK1
SCHEMBL206148 0.84 ALOX5 (0.66) ALOX5VCPMAPTKDM4EMAPK1
SCHEMBL6156291 0.83 MEN1 (0.66) ALOX5VCPMAPTCFTRMEN1
SCHEMBL26126062 0.83 ALOX5 (0.85) ALOX5VCPMAPTKDM4EMAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20030220380-A1 Substituted thiazoles and the use thereof as inhibitors of plasminogen activator inhibitor-1 3-DIMENSIONAL PHARMACEUTICALS, INC. 2003-11-27 US claimed
US-6586453-B2 Useful in prophylaxis or treatment of thrombosis, angina, pectoris, cerebral infarction, myocardial/pulmonary infarction, intra-atrial thrombus in atrial fibrillation, diabetic complications, restenosis, and stroke 3-DIMENSIONAL PHARMACEUTICALS, INC. 2003-07-01 US claimed
US-20010044545-A1 Substituted thiazoles and the use thereof as inhibitors of plasminogen activator inhibitor-1 3-DIMENSIONAL PHARMACEUTICALS, INC. 2001-11-22 US claimed
US-20030220380-A1 Substituted thiazoles and the use thereof as inhibitors of plasminogen activator inhibitor-1 3-DIMENSIONAL PHARMACEUTICALS, INC. 2003-11-27 US disclosed
US-6586453-B2 Useful in prophylaxis or treatment of thrombosis, angina, pectoris, cerebral infarction, myocardial/pulmonary infarction, intra-atrial thrombus in atrial fibrillation, diabetic complications, restenosis, and stroke 3-DIMENSIONAL PHARMACEUTICALS, INC. 2003-07-01 US disclosed
US-20010044545-A1 Substituted thiazoles and the use thereof as inhibitors of plasminogen activator inhibitor-1 3-DIMENSIONAL PHARMACEUTICALS, INC. 2001-11-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20010044545-A1 Substituted thiazoles and the use thereof as inhibitors of plasminogen activator inhibitor-1 SERPINE1, SERPINC1, SERPINB1 ALOX5 2040/4885VCP 2778/4885MAPT 2307/4885
US-20030220380-A1 Substituted thiazoles and the use thereof as inhibitors of plasminogen activator inhibitor-1 SERPINE1, SERPINC1, SERPINB1 ALOX5 2040/4885VCP 2778/4885MAPT 2307/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.